Latest Biotech News

Inhibrx said an OX40–Keytruda combination continued to show early clinical promise, with data indicating the regimen doubled response rates in midphase results. The update comes amid broader M&A...

Pharma dealmaking accelerated in early 2026, with companies completing more transactions and reporting higher upfront values than in the same period last year, according to a compiled M&A tracker....

Novo Nordisk is moving an early-stage Parkinson’s cell therapy into a new biotech home, reflecting continued reshuffling of development assets across cellular and gene-therapy platforms. In a...

Bioscience Co. Ltd. received FDA IND clearance for 9MW5211 as a treatment for inflammatory bowel disease, marking a new step toward first-in-human development. The clearance gives the program...

enGene’s Phase II LEGEND trial update for detalimogene in high-risk BCG-unresponsive nonmuscle invasive bladder cancer triggered a sharp stock drop, with investors reacting to declining complete...

JACIE completed the first-ever inspection under the third edition Immune Effector Cells (IEC) Standards at Guy’s and St Thomas’ NHS Foundation Trust, expanding certification pathways for centers...

Columna Capital agreed to acquire Evidenze Group to expand CRO services across Europe, adding a trials contractor with operations across Spain, Germany, Italy, and Portugal plus a partner network...

Windward Bio secured $165 million to fund clinical trials in asthma, COPD, and additional respiratory and dermatology indications. The company’s long-acting antibody programs are positioned to...

Scientists mapped how diverse HIV-1 strains evade broadly neutralizing antibodies, detailing multiple molecular routes to immune escape. The study by Stabell, Lee, Park and colleagues describes...

European regulators have cleared Fractyl Health to begin a clinical study of a GLP-1 gene therapy candidate. The decision adds momentum to efforts to replace chronic GLP-1 injections and pills...

Inhibrx said its OX40 agonist paired with Merck’s Keytruda doubled response rates in a midphase clinical trial, encouraging advancement of the combination program. The early data arrive amid...

enGene’s Phase II LEGEND update for its nonviral gene therapy detalimogene in high-risk BCG-unresponsive NMIBC showed lower complete response and durability than prior readouts, triggering a sharp...

Roche agreed to acquire PathAI for $750 million upfront to expand AI-powered digital pathology tools for biopharma and pathology labs. The deal targets workflow and analysis capabilities that can...

Windward Bio secured $165 million to fund clinical trials of long-acting antibody programs in respiratory diseases and related indications. The financing supports a lead program in asthma and...

Neion Bio is advancing an avian bioreactor concept designed to manufacture proteins using genetically engineered chickens that produce target proteins in eggs. The company positions the approach...

10x Genomics introduced Atera, an in situ spatial biology platform built to deliver whole-transcriptome spatial analysis with single-cell sensitivity at scale. The platform is designed for both...

Researchers developed a cell-based infection model for rhinovirus C (RV-C), aiming to overcome longstanding experimental constraints around studying the virus. Published in npj Viruses, the...

CSL slumped to a nine-year low after warning of lower full-year revenue guidance and announcing a $5 billion impairment charge. The company linked the update to a revised outlook that includes...

A new report focuses on making protein language models (pLMs) safer and more transparent as they become embedded in protein design workflows. The piece outlines how current pLM...

Roche announced it will acquire PathAI for $750 million upfront, aiming to expand AI-powered capabilities in digital pathology workflows. The deal targets PathAI’s technology used by pathology...